Results 51 to 60 of about 526 (152)

Towards Mechanism‐Informed Treatments for Mental Health

Journal of Neurochemistry, Volume 170, Issue 5, May 2026.
Neuropsychiatric disorders impose a major global health burden, and current treatments, which historically mostly targeted dopamine and serotonin dysfunctions, often provide only partial, symptomatic relief. This review highlights emerging evidence that additional neuromodulator systems, including acetylcholine, norepinephrine, and endocannabinoids ...
Iker Bengoetxea de Tena, Farhanah Nabilah Sallie, Arvie Rodriguez Abiero, Beatrice Rizzi, Leandro Gabriel Champarini, Elisa Corti, Gianluca Masella, Ariel L. Dunn, Luisa Bandeira Binder, Tyler J. Wenzel, Agustin I. Robles, Roberta G. Anversa, Cécilia Tremblay, Aliance Romain Fokoua, Randriely Merscher Sobreira de Lima, Mateus D'Ávila, Trang T. T. Truong, Jessica C. Pierce, Rui S. Rodrigues, Luis Dinamarca‐Villarroel, Felipe Borges Almeida, Aino‐Kaisa Piironen, Andrey F. L. Aguiar, Andrés M. Jaramillo, Lucas Santos, Anja de Lange, David J. Nutt, Andrew J. Lawrence   +27 more
wiley   +1 more source

SOLRIAMFETOL TITRATION AND ADMINISTRATION: DOSING AND TITRATION STRATEGIES IN PATIENTS WITH OSA STARTING SOLRIAMFETOL [PDF]

Chest, 2021
HARAMANDEEP SINGH, DANIELLE HYMAN, GREGORY PARKS, ABBY CHEN, CATHERINE FOLEY, DIANE ITO, MICHAEL THORPY   +6 more
openaire   +1 more source

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review

Brain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor‐e‐Ainaa, Hania Imran, James Hanna, Said Hamid Sadat   +12 more
wiley   +1 more source

Narcolepsy 2025 (with an Australasian perspective)

Internal Medicine Journal, Volume 55, Issue 11, Page 1805-1813, November 2025.
Abstract Narcolepsy is a disorder of central hypersomnolence, which, while uncommon, can carry profound implications for affected individuals. Despite this, it remains under‐recognised within the medical community and presents frequent diagnostic and treatment challenges in the Australasian setting.
Amelia Lin, Brendon J Yee, Jian Eu Tai, Sheila Sivam   +3 more
wiley   +1 more source

Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers

Brain and Behavior, Volume 15, Issue 10, October 2025.
Orexin deficiency drives narcolepsy Type 1, leading to excessive daytime sleepiness, cataplexy, and REM intrusions. This review highlights recent advances (2023–2025) in molecular mechanisms, diagnostics, and emerging orexin‐targeted therapies with the potential for disease modification.
Rameesha Rauf, Salwa Asif, Abdallah AlSaafeen, Kaviprada Geathaa Dhantapaani, Maryam Muhammad Nadeem, Zohra Kamran Rao, Aliya Shaju Shahul Hameed, Karthik Chintharala, Muhammad Faheem Anwar, Asad Ali Ahmed Cheema   +9 more
wiley   +1 more source

Corrigendum: A Randomized Study of Solriamfetol for Excessive Sleepiness in Narcolepsy [PDF]

Annals of Neurology, 2019
openaire   +2 more sources

Present and Future of Central Disorders of Hypersomnolence

Journal of Sleep Research, Volume 34, Issue 5, October 2025.
ABSTRACT Central disorders of hypersomnolence (CDH) are rare neurological conditions lumped by excessive daytime sleepiness (EDS) as primary complaint mostly arising at young age, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and Kleine‐Levin syndrome (KLS). Advances in clinical and translational research have
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

A scoping review of clinical approach and personalized management of obstructive sleep apnea

Journal of Association of Pulmonologist of Tamil Nadu
Obstructive sleep apnea (OSA) is common yet frequently underdiagnosed. It not only impairs the sleep quality but also associated with multiple comorbidities. This review article aims at providing an update on the diagnosis and management of OSA through a
Nileena Namboodiripad Kakkattu Mana, Gomathi Dhamodaran, Ashok Kumar Balan, Vivekanand Vishnampettai Varadarajan, Nagarajan Ramakrishnan   +4 more
doaj   +1 more source

Solriamfetol for attention deficit hyperactivity disorder [PDF]

CNS Spectrums, 2021
Ahmed, Naguy, Adel, El-Sheshaie, Dalal H, Elsori, Bibi, Alamiri   +3 more
openaire   +2 more sources

0756 Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion

Sleep, 2022
Abstract Introduction Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition ...
Hema Gursahani, Thierry Jolas, Maryse Martin, Sandrine Cotier, Sandrine Hughes, Wayne Macfadden   +5 more
openaire   +1 more source